By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
By Pia Rivera
HTG Molecular Diagnostics leads the list of last week’s life science gainers on the NASDAQ, followed by La Jolla Pharmaceutical, Dynavax Technologies, NewLink Genetics and BioCryst Pharmaceutical.
ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced encouraging data from a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo.
Results from the study entitled “In vivo genome editing with a small Cas9 orthologue derived
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced updated data from the ongoing gene therapy clinical trial for Sanfilippo syndrome Type A (MPS IIIA), at the 13th Annual WORLDSymposium™ 2017 lysosomal storage disorders conference in San Diego, CA. The
By Pia Rivera
Editas Medicine (NASDAQ:EDIT) reported that the US Patent and Trademark Office has issued a favorable decision in the CRISPR interference between the University of California, the University of Vienna, Emmanuelle Charpentier and the Broad Institute, Inc. (Broad) regarding certain CRISPR-Cas9 patents the Company exclusively licenses from Broad.
As quoted in